| Title | Phase II Trial Testing the Antiemetic Efficacy of a Single-day Low Dose Aprepitant (or Fosaprepitant) Added to a 5-HT3 Receptor Antagonist Plus Dexamethasone in Patients Receiving Carboplatin |
|---|---|
| Disease/Condition | Oncology (Medical/Hematologic),Cancer |
| Description | |
| Eligibility Criteria | Click here for eligibility requirements |
| Principal Investigator | Richard Gralla, MD |
| Contact Name | Karine Darbinyan |
| Contact Email | kadarbin@montefiore.org |
| Protocol Number | 2015-5109 |
| Inclusion/Notes | This Information was obtained from ClinicalTrials.gov |
| Status | Active/Enrolling |
| Adult Clinical Trial | Yes |
| Pediatric Clinical Trial | No |
| Sub-Specialty | Medical and Hematologic Oncology |
| Adult, Pediatric, Both | Adult |